TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Contributed by: Business Wire

Logo

Tags

Research

General Health

Pharmaceutical

Oncology

Infectious Diseases

Clinical Trials

Science

Cardiology

Biotechnology

Neurology

Other Science

Health

non-exclusive License and Supply Agreement with Lonza

More Like This

TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

EnginZyme Produces Key mRNA Vaccine Ingredient Using Biocatalysis

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases